Table 2. Univariate and multivariate analysis for recurrence-free survival.
| Factors | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| All cases (n = 267) | |||||||
| Age (y.o.) | ≤40 vs. 41≤ | 1.73 | 0.32–1.14 | 0.1074 | |||
| Tumor size | T2, T3 vs. T1 | 2.70 | 1.56–4.93 | 0.0003 | 2.00 | 1.06–3.96 | |
| LN meta. | positive vs. negative | 2.59 | 1.55–4.41 | 0.0003 | 1.94 | 1.07–3.54 | |
| Nuclear grade | 3 vs. 1, 2 | 2.10 | 1.22–3.65 | 0.0076 | 1.49 | 0.77–2.89 | |
| ER | positive vs. negative | 0.50 | 0.30–0.84 | 0.0099 | 0.97 | 0.42–2.21 | |
| PR | positive vs. negative | 0.40 | 0.23–0.67 | 0.0005 | 0.44 | 0.20–0.97 | |
| HER2 | positive vs. negative | 1.98 | 1.09–3.45 | 0.0253 | 1.00 | 0.50–1.96 | |
| APOBEC3B mRNA | high vs. low | 1.76 | 1.05–3.02 | 0.0324 | 1.26 | 0.71–2.31 | |
| ER-negative cases (n = 76) | |||||||
| Age (y.o.) | ≤40 vs. 41≤ | 1.13 | 0.27–3.26 | 0.8480 | |||
| Tumor size | T2, T3 vs. T1 | 3.49 | 1.47–9.60 | 0.0037 | 2.49 | 1.01–7.03 | 0.0463 |
| LN meta. | positive vs. negative | 4.50 | 1.97–11.1 | 0.0003 | 3.63 | 1.56–9.19 | 0.0027 |
| Nuclear grade | 3 vs. 1, 2 | 0.74 | 0.30–2.06 | 0.5350 | |||
| PR | positive vs. negative | 0.55 | 0.03–2.61 | 0.5229 | |||
| HER2 | positive vs. negative | 1.27 | 0.56–2.80 | 0.5521 | |||
| APOBEC3B mRNA | high vs. low | 0.66 | 0.29–1.61 | 0.3420 | |||
| ER-positive cases (n = 191) | |||||||
| Age (y.o.) | ≤40 vs. 41≤ | 2.47 | 1.08–5.14 | 0.0329 | 3.44 | 1.37–7.94 | |
| Tumor size | T2, T3 vs. T1 | 2.29 | 1.13–5.00 | 0.0207 | 2.43 | 1.13–5.69 | |
| LN meta. | positive vs. negative | 1.72 | 0.87–3.44 | 0.1151 | |||
| Nuclear grade | 3 vs. 1, 2 | 2.63 | 1.24–5.49 | 0.0127 | 2.07 | 0.92–4.30 | |
| PR | positive vs. negative | 0.39 | 0.19–0.90 | 0.0282 | 0.31 | 0.14–0.74 | |
| HER2 | positive vs. negative | 2.22 | 0.82–5.12 | 0.1102 | |||
| APOBEC3B mRNA | high vs. low | 2.07 | 1.05–4.19 | 0.0364 | 1.41 | 0.67–3.01 | |
| ER-positive with adjuvant endocrine therapy cases (n = 147) | |||||||
| Age (y.o.) | ≤40 vs. 41≤ | 1.89 | 0.53–5.27 | 0.2938 | |||
| Tumor size | T2, T3 vs. T1 | 1.70 | 0.67–4.86 | 0.2679 | |||
| LN meta. | positive vs. negative | 1.13 | 0.44–2.81 | 0.7853 | |||
| Nuclear grade | 3 vs. 1, 2 | 1.93 | 0.67–5.04 | 0.2103 | |||
| PR | positive vs. negative | 0.23 | 0.07–0.74 | 0.0160 | 0.30 | 0.11–0.97 | 0.0440 |
| HER2 | positive vs. negative | 1.47 | 0.24–4.47 | 0.5592 | |||
| APOBEC3B mRNA | high vs. low | 3.73 | 1.47–10.6 | 0.0052 | 3.28 | 1.27–9.45 | 0.0138 |
| ER-positive and LN-negative cases (n = 117) | |||||||
| Age (y.o.) | ≤40 vs. 41≤ | 1.97 | 0.55–5.81 | 0.2727 | |||
| Tumor size | T2, T3 vs. T1 | 3.81 | 1.33–12.4 | 0.0121 | 3.40 | 1.00–13.4 | 0.0493 |
| Nuclear grade | 3 vs. 1, 2 | 3.32 | 1.06–10.1 | 0.0394 | 1.54 | 0.44–5.31 | 0.4875 |
| PR | positive vs. negative | 0.69 | 0.19–4.45 | 0.6460 | |||
| HER2 | positive vs. negative | 4.08 | 1.11–12.3 | 0.0356 | 2.73 | 0.63–10.7 | 0.1672 |
| APOBEC3B mRNA | high vs. low | 3.57 | 1.27–11.5 | 0.0158 | 4.51 | 1.31–18.3 | 0.0169 |
LN meta.; lymph node metastasis, ER; estrogen receptor, PR; progesterone receptor